Breast Cancer Clinical Trial
Official title:
Risk Assessment Tool for Breast Cancer in Saudi Arabia
This study will have great impact and influence in the medical setting as the targeted model that will be derived from this study will be the pioneer in our region. This model will be beneficial in identifying risk factors and its association with the Arab women population. Furthermore, it will bring chemotherapy prevention once the risk factors and the model are established. Risk factors maybe different from those identified in western women by Gail and IBIS Models
Breast cancer is the most common cancer worldwide. Incidence and mortality have reached a
plateau and appear to be dropping in both United States and parts of Western Europe. This
decline has been attributed to several factors such as early detection through the use of
screening mammography and appropriate use of systemic adjuvant therapy. Breast cancer is a
disease and that is predominantly influenced by risk factors which can be allocated to one
of four groups: first, family history / genetic which accounts for 15% of all breast cancer
cases. The second group which is the most known risk factor for breast cancer can be linked
to hazardous effects of hormonal exposures such as early age at menarche, late age at
menopause, small number of children and nulliparity, late age at first birth and little or
no breast feeding. Long term use of hormone replacement therapy but apparently not long term
use of oral contraceptives is also important. The third group is high mammographic breast
density which has been shown to be one of the most significant markers of breast cancer risk
and the fourth group is having a history proliferative benign breast disease.
Recently, there is a belief that overall caloric intake and obesity in particular with
weight gain are related to increased breast cancer risk with different effects between pre
and post menopausal women. Also physical activity appears to be important, above and beyond
its effect on weight.
There are scattered studies about breast cancer risk factors in the Arab region. One study
was published on March 2002 which investigates risk factors associated with breast cancer in
Jordanian women while some studies associate diet with breast cancer. The known /
well-established risk factors in the Western countries have not bee systematically validated
or proven to play a role in Arab women with breast cancer. Therefore, there is no known risk
assessment tool that is applicable to our patient population. No model has not been created
yet synthesizing the breast cancer risk factors in Arab women.
Research Impact:
This study will have great impact and influence in the medical setting as the targeted model
that will be derived from this study will be the pioneer in our region. This model will be
beneficial in identifying risk factors and its association with the Arab women population.
Furthermore, it will bring chemotherapy prevention once the risk factors and the model are
established. Risk factors maybe different from those identified in western women by Gail and
IBIS Models
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |